Bruce Samuels
Latest contributions
New evidence for coronary revascularisation
21 May 2026 – From EuroPCR 2026
This session highlights new evidence in coronary revascularisation, including the role of CT-derived virtual stenting for procedural optimization, left ventricular unloading during complex PCI, long-term outcomes of FFR-guided PCI versus medical therapy, Impella CP support in high-risk PCI, and comparative results of PCI versus CABG in...
New evidence in coronary physiology for microvascular assessment
21 May 2026 – From EuroPCR 2026
This session highlights new evidence in coronary physiology related to microvascular assessment. Topics include endothelial dysfunction in angina with non-obstructive arteries, the prognostic value of microvascular resistance metrics, natural history studies, and trials aimed at standardizing management of microvascular dysfunction.
Early evidence from a next generation coronary sinus reducer for the treatment of coronary microvascular dysfunction
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents early clinical experience with a next-generation self-expanding nitinol coronary sinus reducer for patients with coronary microvascular dysfunction. It reviews practical aspects of device implantation and discusses initial findings from the SERRA I feasibility study, providing insight into this emerging therapeutic approach....
How a new generation of coronary sinus reducer can significantly expand treatment options for patients with coronary microvascular dysfunction
21 May 2025 – From EuroPCR 2025
Discover the latest on managing coronary microvascular dysfunction (CMD) with insights from EuroPCR 2025. This session explores how physiology testing helps identify CMD endotypes in the cathlab and highlights the limitations of ETT for patients experiencing angina or dyspnea at rest. Learn about the A-FLUX coronary...
